FHA
NKTR icon

Flagship Harbor Advisors’s Nektar Therapeutics NKTR Stock Holding History

Flagship Harbor Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,179
Closed -$92.1K – 1660
2025
Q4 		$92.1K Buy
+2,179
New +$122K ﹤0.01% 889
2023
Q2 		– Sell
-703
Closed -$7.42K – 640
2023
Q1 		$7.42K Buy
+703
New +$21.3K ﹤0.01% 618
2020
Q4 		– Sell
-471
Closed -$117K – 1305
2020
Q3 		$117K Hold
471
– – 0.02% 610
2020
Q2 		$163K Hold
471
– – 0.02% 509
2020
Q1 		$126K Buy
471
+175
+59% +$54.1K 0.03% 488
2019
Q4 		$96K Sell
296
-136
-31% -$39.4K 0.02% 619
2019
Q3 		$117K Hold
432
– – 0.02% 542
2019
Q2 		$230K Buy
432
+58
+16% +$29.1K 0.05% 365
2019
Q1 		$188K Buy
374
+56
+18% +$33.2K 0.04% 413
2018
Q4 		$156K Buy
318
+39
+14% +$23.5K 0.04% 418
2018
Q3 		$237K Buy
279
+85
+44% +$72.6K 0.04% 367
2018
Q2 		$142K Buy
+194
New +$224K 0.03% 478

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Harbor Advisors's NKTR Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 2,179 shares — an estimated $92.1K sold.

Flagship Harbor Advisors first reported a position in NKTR in Q2 2018 and held it in 12 quarters. The position peaked at $237K in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 2,179 Nektar Therapeutics shares in Q1 2026, an estimated $92.1K.
  • Flagship Harbor Advisors first reported a position in Nektar Therapeutics in Q2 2018 and held it in 12 quarters.
  • Flagship Harbor Advisors's Nektar Therapeutics position peaked at $237K in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.